Orphan designation: marketing authorisation

  • Email
  • Help

The European Medicines Agency (EMA) is responsible for the scientific evaluation of marketing authorisation applications for all orphan medicines in the European Economic Area, as they fall under the mandatory scope of the centralised procedure.

In this section

 
In other sections

Sponsors of designated orphan medicines at the marketing authorisation stage should also consider the regulatory information in the sections below:

How useful is this page?

Average rating:

 Based on 2 ratings

Add your rating:

See all ratings
0 ratings
1 ratings
0 ratings
0 ratings
1 ratings

Related content